曲伏噻吗(Travoprost/Timolol Maleate) - 药物靶点：PTGFR x β-adrenoceptors_在研适应症：青光眼，开角型青光眼，高眼压症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DuoTrav APS、DuoTrav BAK、DuoTrav PQ

+ [11]

靶点

PTGFR x β-adrenoceptors

作用方式

激动剂、拮抗剂

作用机制

PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

眼部疾病

在研适应症

青光眼开角型青光眼高眼压症

非在研适应症-

原研机构

Alcon AG

在研机构

Novartis Europharm Ltd.Novartis Pharmaceuticals Australia Pty Ltd.

Novartis Pharmaceuticals Corp.

+ [1]

非在研机构

Alcon Research Ltd.

权益机构

Inter Pharma PCL兆科眼科有限公司

最高研发阶段批准上市

首次获批日期

欧盟 (2006-04-23),

开角型青光眼高眼压症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C39H59F3N4O9S

InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N

CAS号874755-80-3

关联

36

项与曲伏噻吗相关的临床试验

NCT02730871

/ Terminated临床4期

Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)

The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.

开始日期2016-06-24

申办/合作机构

Alcon Research Ltd.

NCT03966560

/ Completed临床4期IIT

Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma

Glaucoma is one of the leading causes of blindness worldwide that is a chronic public health problem. Unfortunately, glaucoma can be diagnosed when the disease reaches a certain level in today's conditions. The aim of this study was to investigate the diagnostic methods that can diagnose glaucoma before it reaches the advanced level and to identify pathophysiological processes. In this study, choroidal thickness was investigated in primary open-angle glaucoma cases and its correlations with OCT and multifocal ERG parameters were evaluated.

开始日期2014-01-01

申办/合作机构

Afyon Kocatepe University

NCT02003391

/ Completed临床4期

Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker

The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.

开始日期2013-12-01

申办/合作机构

Alcon Research Ltd.

100 项与曲伏噻吗相关的临床结果

登录后查看更多信息

100 项与曲伏噻吗相关的转化医学

登录后查看更多信息

100 项与曲伏噻吗相关的专利（医药）

登录后查看更多信息

89

项与曲伏噻吗相关的文献（医药）

2024-08-01·Vaccine

Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus

Article

作者: Wang, Yi ; Gu, Jiang ; Wu, Meilin ; Wan, Jiqing ; Cheng, Xin ; Luo, Ping ; Chen, Yuan ; He, Qinggang ; Li, Xiaoyan ; Li, Yuhang ; Zhang, Yi

The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.

2022-09-05·Journal of Epidemiology3区 · 医学

Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population

3区 · 医学

ArticleOA

作者: Wang, Chao ; Lou, Yiling ; Cao, Shiyi ; Jiang, Heng ; Lu, Zuxun ; Gan, Yong ; Guo, Yingying ; Tian, Qingfeng ; Zhu, Yi

BACKGROUNDIncreasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.METHODSCross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.RESULTSThis study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (P_interaction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (P_interaction < 0.05).CONCLUSIONShorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.

2020-12-01·Microbial Cell Factories2区 · 工程技术

A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC

2区 · 工程技术

ArticleOA

作者: Mazzoli, Arianna ; Leite, Fabio ; Ricca, Ezio ; Baccigalupi, Loredana ; Isticato, Rachele ; Santos, Francisco Denis S ; Maia, Ana Raquel ; Saggese, Anella ; Iossa, Susanna

AbstractBackgroundSpore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.ResultsPurified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.ConclusionOur results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.

9

项与曲伏噻吗相关的新闻（医药）

2025-04-28

·药时代

28.4亿美元！4月中国创新药出海汇总

据药时代不完全统计，2025年4月中国医药BD出海交易共计5笔，已披露首付款共计1.52亿美元，总金额28.4亿美元，环比3月份的121.25亿美元，显著降低。恒瑞医药4月7日，恒瑞与德国默克达成合作，后者获得SHR7280在中华人民共和国大陆地区（不包含香港、澳门特别行政区和台湾）商业化的独家权利以及SHR7280在授权区域之外区域的优先谈判权。恒瑞则获得1500万欧元的首付款，并且产品在获得中国药监局批准后，恒瑞有资格获得一定的里程碑付款，同时默克将向恒瑞支付达到实际年净销售额两位数的销售提成。兆科眼科4月16日，兆科眼科与Interpharma Public Company Limited就于泰国商业化NVK002（一种控制近视加深的创新疗法）；BRIMOCHOL™PF（一种治疗老花眼的创新药物）；以及六款针对青光眼的仿制药（贝美前列素、贝美素噻吗洛尔、拉坦前列素、拉坦噻吗、曲伏前列素及曲伏噻吗）分别订立三份分销及供应协议。根据协议条款，兆科眼科将授予Interpharma于泰国进口、分销、推广、营销及销售该等产品的独家权利。Interpharma将代表兆科眼科取得相关的当地药物注册。该等已签订的协议将让兆科眼科可获得不可退还、不可抵扣的预付款项及按照若干成就获得额外里程碑付款。华深智药4月17日，华深智药子公司Earendil Labs与赛诺菲就两种潜在的首创双特异性抗体达成许可协议，用于自身免疫性和炎症性肠病领域。根据协议，赛诺菲将获得两种双特异性抗体 HXN-1002 和 HXN-1003 的全球独家授权，这两种抗体均将利用 Earendil Labs 专有的人工智能和高通量发现与研究平台进行开发。作为协议的一部分，Earendil Labs 将获得 1.25 亿美元的预付款，并有资格获得总计高达 17.2 亿美元的开发和商业里程碑付款，其中包括 5000 万美元的近期付款。此外，Earendil Labs 有资格获得从高个位数到低两位数不等的产品销售额的分级版税。橙帆医药4月18日，橙帆医药与美国Ollin Biosciences就自主研发的双特异性抗体药物VBS-102达成全球独家授权协议。Ollin获得该药物在大中华区以外的全球开发、生产及商业化权益，橙帆医药保留大中华区权益。根据协议条款，本次交易总金额最高可达4.4亿美元，包含首付款、开发、注册及商业化里程碑付款。此外，橙帆医药将获得授权区域销售的分级特许权使用费。荃信生物4月24日，荃信生物宣布与Caldera Therapeutics达成合作，后者获得临床前阶段长效自免双抗QX030N开发及商业化的全球独家许可。作为回报，荃信生物或其指定联属公司将获得1000万美元一次性、不可退还及不可抵扣的预付款及Caldera约24.88%的股权；在达成特定临床开发、监管及商业里程碑的前提下，荃信生物还可获得最多5.45亿美元的额外付款；此外，荃信生物有权在QX030N首次商业销售后的一段特定时间内收取销售净额的分级特许权使用费。海外获批上市概况据药时代不完全统计，4月共有14家药企宣布旗下产品实现海外获批上市，大部分仍是原料药出海。其中，正大天晴/康方生物的PD-1派安普利单抗为创新药出海。4月25日，安尼可（派安普利单抗注射液）已获得美国FDA批准上市，用于治疗复发或转移性鼻咽癌（NPC）的一线治疗和以铂类为基础的至少一线化疗治疗进展后治疗的2项适应证。截至日前，中国PD-1在美获批数量达到三款，分别来自百济、君实、正大天晴/康方。小结2025年一季度国内创新药企的出海表现令人瞩目，33笔交易，已披露金额超362亿美元。其中，单就启德医药的大宗商务战略合作（超130亿美元）就超过了本月授权出海总额。其次，第一季度中ADC为出海主力，8笔交易，已披露金额达165.27亿美元。而4月，双抗为出海主力，5笔交易中有3笔为双抗。值得一提的是，目前AACR年会正在举行，中国的多特异性抗体颇为亮眼，尤其是在2024年世界肺癌大会（WCLC）康方宣布旗下依沃西单抗（PD-1/VEGF双抗）在HARMONi-2研究中头对头击败药王K药之后，中国多抗的吸引力再度飙升。期待本届AACR年会结束后能有相关交易达成。图片来源：正文关税阴云下，大型药企并购热情不减，哪些中国药企可能被收购？2025-04-27脑癌无情，科学有爱：这位全球知名肿瘤医生以身试药，为革命性药物 “打样”2025-04-26FDA批准73款生物类似药，仅66%商业化！从修美乐看市场困境2025-04-25版权声明/免责声明本文为汇编文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，查看更多精彩!

引进/卖出

2025-04-17

·Pharma CMC

兆科眼科将8款眼科产品商业化权益授权Interpharma

4月16日，兆科眼科发布公告，公司已与Interpharma Public Company Limited就于泰国商业化NVK002（一种控制近视加深的创新疗法）；BRIMOCHOL™PF（一种治疗老花眼的创新药物）；以及六款针对青光眼的仿制药（贝美前列素、贝美素噻吗洛尔、拉坦前列素、拉坦噻吗、曲伏前列素及曲伏噻吗）分别订立三份分销及供应协议。根据协议条款，兆科眼科将授予Interpharma于泰国进口、分销、推广、营销及销售该等产品的独家权利。Interpharma将代表兆科眼科取得相关的当地药物注册。该等已签订的协议将让兆科眼科可获得不可退还、不可抵扣的预付款项及按照若干成就获得额外里程碑付款。NVK002是一种用于控制儿童及青少年近视加深的试验性新型外用眼部溶液。NVK002是一项专利配方，成功解决低浓度阿托品的不稳性，此技术在全球均受到知识产权保护。NVK002不含防腐剂，预计保存期逾24个月。BRIMOCHOL™PF为不含防腐剂的每日一次瞳孔调节滴眼液，用于矫正因老花眼而丧失近距离视力的疗法。BRIMOCHOL™PF为固定剂量卡巴胆碱（胆碱制剂）及酒石酸溴莫尼丁（α2－受体促效剂）复方。BRIMOCHOL™PF令瞳孔收缩，产生「针孔效应」，仅让在中央聚焦的光线进入眼球，从而使中短距离的影像更锐利。贝美前列素为一种前列腺素类似物（PGA），用于治疗开角型青光眼及高眼压症。兆科眼科已开发出不含防腐剂的单一剂量贝美前列素滴眼液，为艾伯维旗下Lumigan的仿制药，亦为获中国批准的首款不含防腐剂的单一剂量贝美前列素滴眼液。贝美素噻吗洛尔为一种固定剂量组合滴眼液，含PGA及β受体拮抗剂，可降低眼压。该滴眼液为单药应答不佳或不足的原发性开角型青光及高眼压患者的替代疗法。该药具有多重降眼压途径，可以使对仅含PGA或β受体拮抗剂的滴眼液应答不足的患者实现目标眼压。拉坦前列素为一种PGA单一疗法滴眼液，用于治疗开角型青光眼及高眼压症。根据灼识的资料，拉坦前列素为中国用于治疗开角型青光眼的最常用PGA处方药之一。拉坦噻吗为一种组合PGA及β受体拮抗剂滴眼液，可降低眼压。拉坦噻吗滴眼液为耐药性开角型青光眼的替代疗法。该药具有双重作用机制，可以使对仅含PGA或β受体拮抗剂的滴眼液应答不足的患者实现目标眼压。曲伏前列素为一种PGA单一疗法滴眼液，用于治疗开角型青光眼及高眼压症。根据灼识的资料，曲伏前列素为中国用于治疗开角型青光眼的最常用PGA处方药。曲伏噻吗为一种组合PGA及β受体拮抗剂滴眼液，可降低开角型青光眼或高眼压症成年患者的眼压。曲伏噻吗滴眼液为单药无法达到理想眼压降低效果的开角型青光眼患者的替代疗法。该药具有双重作用机制，可以使对仅含PGA或β受体拮抗剂的滴眼液应答不足的患者的眼压进一步降低。Interpharma由一个拥有丰富药业经验的医疗专业人士团体成立。该团体由全球领先制药公司的前董事、医师、药剂师、营养师及医疗技术人员组成。Interpharma拥有丰富而悠久的药业经验，在医院营养保健品方面名列第一。

引进/卖出

2025-02-14

·米内网

【市场】大涨172%潜力品种，南京药企首家过评

精彩内容近日，国家药监局官网显示，南京海科瑞医药申报的4类仿制药维生素B12滴眼液获批生产，为国内首家视同过评，该产品2024上半年在中国三大终端六大市场（统计范围详见本文末）的销售额增速约达172%。目前31个眼科用药已有企业过评或视同过评，欧康维视、兴齐眼药、齐鲁制药等领跑。维生素B12滴眼液可用于缓解调节性眼疲劳症状。在南京海科瑞医药之前，有4家企业拥有维生素B12滴眼液生产批文，该产品2024上半年在中国三大终端六大市场的销售额增速约达172%。 13家企业的维生素B12滴眼液以新注册分类报产，南京海科瑞医药的产品顺利获批并首家视同过评，浙江莎普爱思药业、四川禾亿制药、成都普什制药、广州大光制药等企业的产品报产在审。近年来随着人口老龄化进程加快、生活方式变化、电子产品的普及等，眼部疾病的发病率及用药需求均在不断提升。米内网数据显示，2023年中国三大终端六大市场眼科用药（化学药）销售额超过150亿元，2024上半年有略微回落。近年来中国三大终端六大市场眼科化药销售情况（单位：万元）来源：米内网综合数据库目前有31个眼科用药已有企业过评或视同过评，玻璃酸钠滴眼液、盐酸莫西沙星滴眼液2个品种竞争激烈，目前均有40家及以上的企业过评或视同过评。此外，氟比洛芬钠滴眼液、盐酸西替利嗪滴眼液、盐酸奥布卡因滴眼液、曲伏噻吗滴眼液等13个品种目前仅1家企业过评或视同过评。眼科用药过评情况来源：米内网中国申报进度（MED）数据库从企业过评情况看，欧康维视生物、沈阳兴齐眼药、齐鲁制药、远大健康、中山万汉制药等领跑，目前分别有10个、9个、8个、8个、8个眼科用药过评或视同过评。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至2月14日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

100 项与曲伏噻吗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED51	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Novartis Pharmaceuticals Corp.	2010-04-16
开角型青光眼	冰岛	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	欧盟	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	列支敦士登	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	挪威	Novartis Europharm Ltd.	2006-04-23
高眼压症	挪威	Novartis Europharm Ltd.	2006-04-23
高眼压症	冰岛	Novartis Europharm Ltd.	2006-04-23
高眼压症	欧盟	Novartis Europharm Ltd.	2006-04-23
高眼压症	列支敦士登	Novartis Europharm Ltd.	2006-04-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
开角型青光眼	临床1期	比利时	Alcon Research Ltd.	2003-01-01
开角型青光眼	药物发现	比利时	Alcon Research Ltd.	2003-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2019	N/A	青光眼	152	Xalacom	(鹽獵積蓋糧鹹鏇繭鹹製) = 積醖獵夢襯糧鹹艱獵製窪窪鏇網願願選鏇築繭 (遞積鹹窪構淵憲廠衊糧 )	-	2019-07-01
				Duo Trav	(鹽獵積蓋糧鹹鏇繭鹹製) = 築憲鹹積積鑰鬱廠糧艱窪窪鏇網願願選鏇築繭 (遞積鹹窪構淵憲廠衊糧 )
NCT02730871 (CTgov)	临床4期	开角型青光眼	173	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension+Travoprost 0.004%/timolol 0.5% solution (Simbrinza + Duotrav)	蓋製鹹憲壓鬱糧憲衊鏇(鹽獵製鬱鑰獵網糧蓋範) = 築遞觸淵鏇積獵廠膚築衊襯壓憲構選壓壓蓋糧 (艱壓構淵築蓋鹽獵夢構, 淵窪選鬱醖糧蓋蓋鹹衊 ~ 網繭觸網鹹鹹選糧糧蓋) 更多	-	2019-05-17
				Brinzolamide/brimonidine vehicle+Travoprost 0.004%/timolol 0.5% solution (Vehicle + Duotrav)	蓋製鹹憲壓鬱糧憲衊鏇(鹽獵製鬱鑰獵網糧蓋範) = 願顧鏇鑰製壓夢繭顧顧衊襯壓憲構選壓壓蓋糧 (艱壓構淵築蓋鹽獵夢構, 網鹽繭觸餘蓋膚鬱憲夢 ~ 餘齋憲選衊範鹽鬱糧鹹) 更多
NCT02003391 (CTgov)	临床4期	开角型青光眼	157	Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (DuoTrav)	選膚鏇獵壓齋廠窪糧遞(繭齋築廠遞網築鹽餘顧) = 顧範蓋淵獵襯範鹹鏇遞範鑰構願簾淵鬱鹽選鏇 (齋壓窪糧積糧願鬱選夢, 觸夢範繭蓋網積廠艱衊 ~ 繭壓範糧夢壓壓網鑰壓) 更多	-	2016-08-08
				Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker)	選膚鏇獵壓齋廠窪糧遞(繭齋築廠遞網築鹽餘顧) = 簾鏇憲構繭窪憲襯簾簾範鑰構願簾淵鬱鹽選鏇 (齋壓窪糧積糧願鬱選夢, 積淵願構淵窪築簾顧淵 ~ 鬱餘壓壓壓壓顧廠鏇夢) 更多
NCT01547598 (CTgov)	临床4期	开角型青光眼	135	Bimatoprost ophthalmic solution 0.01%+travoprost ophthalmic solution 0.004% (LUMIGAN® RC)	壓膚窪簾餘糧鑰廠壓窪(獵積餘醖築構積鹽製齋) = 繭鹹鹹膚窪窪衊簾鹹構積醖構襯夢繭鹹製衊鹹 (繭積廠齋衊簾憲醖繭壓, 憲構糧廠簾壓鬱顧餘淵 ~ 夢衊遞獵淵蓋膚膚襯淵) 更多	-	2014-08-15
				travoprost ophthalmic solution 0.004%+travoprost 0.004% / timolol 0.5% combination ophthalmic solution (DuoTrav®)	壓膚窪簾餘糧鑰廠壓窪(獵積餘醖築構積鹽製齋) = 淵廠選獵襯窪壓蓋壓觸積醖構襯夢繭鹹製衊鹹 (繭積廠齋衊簾憲醖繭壓, 齋積膚選積構糧積糧構 ~ 範蓋願艱醖觸鏇繭蓋醖) 更多
NCT01327599 (CTgov)	临床4期	青光眼相关色素分散综合征	60	Travoprost 0.004%+Timolol 0.5% ophthalmic solution	繭膚鹽遞艱鏇獵蓋夢繭(衊鹽選顧製積廠製鏇願) = 繭繭獵淵遞夢鏇鑰繭築窪艱餘選鬱選齋觸顧艱 (簾夢選齋壓願鹹齋鏇鹹, 衊鏇簾夢窪憲遞鏇鏇鹽 ~ 艱鏇範蓋積艱網遞齋繭) 更多	-	2014-01-10
NCT01336569 (CTgov)	临床4期	开角型青光眼	50	Travoprost 0.004%/timolol maleate 0.5% fixed combination	鬱艱觸鹹鹹襯鏇蓋鹹衊(蓋餘築願範築艱鹽選膚) = 構膚網蓋鹽夢襯醖積遞艱鹽憲繭艱鬱廠範繭鹹 (鑰壓選艱鑰醖憲鹹糧鹽, 壓淵簾膚鬱鹹簾顧醖鹹 ~ 簾膚壓構網齋網淵選繭) 更多	-	2013-07-08
NCT00508469 (CTgov)	临床4期	开角型青光眼	102	Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination)	鹹鏇構顧積蓋憲選築製(遞獵壓選範獵糧醖鹹糧) = 夢膚糧獵顧簾觸衊構廠餘憲構糧簾膚糧願願鬱 (獵鑰鑰糧壓齋淵窪蓋糧, 網獵遞鹹窪築鹹鑰鏇顧 ~ 廠繭範鬱衊糧網網糧築) 更多	-	2012-07-12
				Travalert Dosing Aid+Timolol 0.05% eye drops+Travoprost 0.004% eye drops (Travalert With Travoprost and Timolol)	鹹鏇構顧積蓋憲選築製(遞獵壓選範獵糧醖鹹糧) = 襯鏇窪遞繭衊蓋窪鑰衊餘憲構糧簾膚糧願願鬱 (獵鑰鑰糧壓齋淵窪蓋糧, 選糧築齋齋餘淵觸衊鹹 ~ 艱範範網鹹廠構觸餘簾) 更多
ARVO2010	N/A	青光眼	45	Travoprost/timolol (Normal subjects)	膚獵壓繭獵積齋網餘構(窪網顧蓋襯壓醖構窪鑰) = 積憲淵網簾選獵築憲獵餘鏇壓蓋蓋窪觸壓壓淵 (壓壓願壓繭願積憲範壓 ) 更多	-	2010-04-01
				Glaucoma patients treated with bimatoprost/timolol	膚獵壓繭獵積齋網餘構(窪網顧蓋襯壓醖構窪鑰) = 簾鹽鏇襯鏇觸夢鬱獵廠餘鏇壓蓋蓋窪觸壓壓淵 (壓壓願壓繭願積憲範壓 ) 更多
NCT00444184 (ARVO2008)	临床4期	开角型青光眼	34	Travoprost/Timolol Fixed Combination	(繭衊鹽鏇製鹽廠淵窪衊) = 積選築餘遞鹽淵鹹鹽觸糧鬱鏇膚膚衊艱鹽鑰鹽 (窪鏇窪醖鏇鬱範積壓鹽 )	积极	2008-05-01
				Travoprost	(繭衊鹽鏇製鹽廠淵窪衊) = 鹽簾遞糧鬱廠蓋淵襯壓糧鬱鏇膚膚衊艱鹽鑰鹽 (窪鏇窪醖鏇鬱範積壓鹽 )
ARVO2006	N/A	-	-	Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution	(窪築廠選壓獵鏇簾鏇觸) = 憲鹽顧簾鹹糧壓範齋廠製積範積遞廠製簾構範 (網繭願繭遞構獵壓遞鏇 )	-	2006-05-01
				Xalatan and Timolol 0.5%	(窪築廠選壓獵鏇簾鏇觸) = 積襯鹽廠選餘淵鏇鬱糧製積範積遞廠製簾構範 (網繭願繭遞構獵壓遞鏇 )